Celltrion Launches its Third Biosimilar Truxima (biosimilar, rituximab) in Brazil

 Celltrion Launches its Third Biosimilar Truxima (biosimilar, rituximab) in Brazil

Celltrion Reports Submission of MAA to EMA for CT-P17 (biosimilar, adalimumab)

Shots:

  • In Jun 2021, the company plans for the closure of supplying Truxima to the state governments and will focus on expanding its footprints with exclusively selling it in Brazil. Truxima’s safety and efficacy is proven as its prescriptions is expanded in the US, EU, and WW
  • Additionally, on May 26th, 2020, Celltrion will launch Truxima Launching Symposium for Key Opinion Leader (KOL) medical personnel in Sao Paulo, Brazil coinciding it with the launch of Truxima and the event involved 500+ medical personnel focusing on COVID-19
  • Truxima is a mAb approved by the US FDA and EMA and released in Latin America will affect impact on neighboring countries including Chile and Ecuador

Click here to read full press release/ article | Ref: Celltrion | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post